Amrita Krishnan, MD
Therapeutic options for relapsed/refractory multiple myeloma are quickly evolving, following an explosion of data presented over the last several months, explained Amrita Krishnan, MD.
For example, results of the phase III COLUMBA trial found that daratumumab (Darzalex) can be given subcutaneously rather than intravenously without comprising efficacy in patients with relapsed/refractory multiple myeloma.1
Based on these data, a supplemental biologics license application was submitted to the FDA
in July 2019 for the new subcutaneous formulation as a treatment for patients with multiple myeloma.
Data have also read out with another CD38-directed monoclonal antibody. In the ICARIA-MM trial, which looked at isatuximab plus pomalidomide (Pomalyst)/dexamethasone versus pomalidomide/dexamethasone alone, findings showed a greater than 40% reduction in the risk of disease progression or death in the isatuximab arm.2
In July 2019, the FDA accepted a biologics license application for isatuximab
for the treatment of patients with relapsed/refractory disease.
... to read the full story